Nurix Therapeutics (NRIX)
(Real Time Quote from BATS)
$12.76 USD
+0.40 (3.24%)
Updated Apr 29, 2024 12:13 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Income Statements
Fiscal Year end for Nurix Therapeutics, Inc falls in the month of November .
All items in Millions except EPS data.
11/30/23 | 11/30/22 | 11/30/21 | 11/30/20 | 11/30/19 | |
---|---|---|---|---|---|
Sales | 77 | 39 | 30 | 18 | 31 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 77 | 39 | 30 | 18 | 31 |
Selling & Adminstrative & Depr. & Amort Expenses | 232 | 223 | 148 | 83 | 53 |
Income After Depreciation & Amortization | -155 | -184 | -118 | -65 | -22 |
Non-Operating Income | 11 | 4 | 1 | 1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -144 | -180 | -117 | -64 | -21 |
Income Taxes | 0 | 0 | 0 | -21 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -144 | -180 | -117 | -43 | -22 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -144 | -180 | -117 | -43 | -22 |
Depreciation Footnote | 11/30/23 | 11/30/22 | 11/30/21 | 11/30/20 | 11/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -147 | -173 | -110 | -63 | -20 |
Depreciation & Amortization (Cash Flow) | 8 | 11 | 8 | 2 | 2 |
Income After Depreciation & Amortization | -155 | -184 | -118 | -65 | -22 |
Earnings Per Share Data | 11/30/23 | 11/30/22 | 11/30/21 | 11/30/20 | 11/30/19 |
---|---|---|---|---|---|
Average Shares | 54.34 | 48.61 | 42.90 | 15.67 | NA |
Diluted EPS Before Non-Recurring Items | -2.65 | -3.71 | -2.73 | -2.76 | NA |
Diluted Net EPS (GAAP) | -2.65 | -3.71 | -2.73 | -2.76 | -6.59 |
Fiscal Year end for Nurix Therapeutics, Inc falls in the month of November .
All items in Millions except EPS data.
2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 | 2/28/23 | |
---|---|---|---|---|---|
Sales | 16.59 | 15.16 | 18.47 | 30.68 | 12.69 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 16.59 | 15.16 | 18.47 | 30.68 | 12.69 |
SG&A, R&D, and Dept/Amort Expenses | 61.81 | 60.49 | 58.48 | 57.44 | 55.64 |
Income After SG&A, R&D, and Dept/Amort Expenses | -45.22 | -45.33 | -40.01 | -26.76 | -42.95 |
Non-Operating Income | 3.79 | 3.38 | 3.03 | 2.49 | 2.22 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -41.43 | -41.96 | -36.98 | -24.28 | -40.73 |
Income Taxes | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -41.52 | -41.96 | -36.98 | -24.28 | -40.73 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -41.52 | -41.96 | -36.98 | -24.28 | -40.73 |
Earnings Per Share Data | 2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 | 2/28/23 |
---|---|---|---|---|---|
Average Shares | 54.90 | 54.67 | 54.39 | 54.26 | 54.03 |
Diluted EPS Before Non-Recurring Items | -0.76 | -0.77 | -0.68 | -0.45 | -0.75 |
Diluted Net EPS (GAAP) | -0.76 | -0.77 | -0.68 | -0.45 | -0.75 |